Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04835935 · ClinicalTrials.gov registry record

Microbiome, Atopic Disease, Prematurity

A clinical trial of Prematurity and Atopy, sponsored by Sydney Leibel.

Active
Registry status
51
Enrollment target
2
Study locations

NCT04835935: Active study of Prematurity and Atopy, sponsored by Sydney Leibel.

NCT04835935 is a study of Prematurity and Atopy that is active but no longer recruiting, run by Sydney Leibel. The registered enrollment target is 51 participants, below the 209-participant average among 21 other Prematurity trials with a reported enrollment target (76% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04835935, a study of Prematurity and Atopy, is active but no longer recruiting, sponsored by Sydney Leibel.

ACTIVE NOT RECRUITING
Registry status
51 participants
Enrollment target
2
Study locations

Study Summary

There is increasing recognition that the microbiome may be important in the development of allergic disease. Asthma is the most prevalent pediatric chronic disease and affects more than 300 million people worldwide. For unclear reasons, those infants born at 34 weeks and earlier are three times as likely to develop asthma. Factors such as formula feeding, C-section delivery and antibiotic exposure may play a role. Recent evidence has identified a "critical window" in early life where gut and breast milk microbial changes are most influential. The investigators propose a novel study to follow a cohort of premature babies in the NICU and after discharge home. The investigators aim to examine whether various exposures of babies in the NICU impact their milk and gut microbiome and lead to asthma and allergies. Our specific aims are: 1. To assess if there is a specific pattern of gut and/or breast milk microbiome over time that is affected by the type of nutrition a baby receives (donor vs maternal vs formula) or other exposures such as antibiotics. 2. Assess whether there are patterns in the microbiome associated with the development of allergic sensitization patterns. 3. Determine if early patterns of the microbiome and allergic sensitization predict allergic conditions (food allergies, allergic rhinitis, eczema, asthma) by 2 years of age. The investigators will recruit approximately 50 subjects born at 34 weeks of gestation or earlier from two local level III NICU. These subjects will be followed over their NICU course with weekly stool, milk feed, and oral saliva collection as well as documentation of relevant events including prenatal history, delivery history, nutrition and breast feeding history and antibiotic courses. Further samples will be collected after discharge at research visits that will take place Rady Children's Hospital until 4-6 years of age. At these visits, standardized allergy questionnaires and a blood allergy panel will be obtained. Together t

Primary Outcome

Clinical diagnosis of any atopic disease among the participants during study follow up visit. These include any food allergies, allergic rhinitis, eczema, and asthma.

Conditions Studied

Interventions

  • OTHER microbiome pattern

Study Locations (2)

California

  • Scripps Memorial Hospital - Rady NICU - San Diego
  • University of California, San Diego - Jacobs NICU - San Diego

Trial Details

FieldValue
Enrollment Target 51 participants
Start Date 2019-06-01
Est. Completion 2030-12-30
Sydney Leibel

1 total trials

What the registry record for NCT04835935 still lists

NCT04835935 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 209-participant average among 21 other Prematurity trials with a reported enrollment target (76% lower).

The record links to 2 conditions, with Prematurity appearing as the primary indexed condition, and to 1 intervention - of which microbiome pattern is the first listed.

NCT04835935 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT04835935 about?

NCT04835935 is a clinical study titled "Microbiome, Atopic Disease, Prematurity". There is increasing recognition that the microbiome may be important in the development of allergic disease. Asthma is the most prevalent pediatric chronic disease and affects more than 300 million people worldwide. For unclear reasons, those infants born at 34 weeks and earlier are three times as l...

What is the current status of trial NCT04835935?

This trial is currently active not recruiting. The enrollment target is 51 participants. The study started on 2019-06-01. Estimated completion is 2030-12-30.

What conditions does trial NCT04835935 study?

This clinical trial studies the following conditions: Prematurity, Atopy.

What interventions are being tested in trial NCT04835935?

The interventions under investigation include: microbiome pattern (OTHER).

Who is sponsoring clinical trial NCT04835935?

This trial is sponsored by Sydney Leibel, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04835935 being conducted?

This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prematurity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04835935's enrollment target sits among peer trials

51 19th of 21 higher than 2 of 21 other Prematurity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prematurity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02701153 · 51 participants · NA

    Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort

  • NCT03663790 · 51 participants · NA

    Effects of Gait Retraining on Lower Extremity Biomechanics

  • NCT03874052 · 51 participants · Phase 1

    Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

  • NCT04704661 · 51 participants · Phase 1

    Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04835935, the US trial registry maintained by the National Library of Medicine. NCT04835935 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.